Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Lancet Oncol. 2022 Jan 12;23(2):292–303. doi: 10.1016/S1470-2045(21)00693-8

Figure 2: Change from baseline in (A) FKSI-19 total score, (B) FKSI-19 DRS-v1 score, (C) EQ-5D-3L VAS score, and (D) EQ-5D-3L UK utility index value – MMRM results.

Figure 2:

Figure 2:

CI=confidence interval. DRSv1=disease-related symptoms version 1. EQ-5D-3L=three-level version of the EQ-5D. FKSI-19=Functional Assessment of Cancer Therapy-Kidney Symptom Index. MMRM=mixed-model repeated measures. SD=standard deviation. SE=standard error.